Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)
The summary for the Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional): Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ?-caryophyllene, Limonene, ?-terpineol, Linalool, ?-phellandrene, ?-pinene, ?-pinene, ?-terpinene, and ?-humulene. This initiative intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to identify, describe and determine whether minor cannabinoids and/or terpenes can help treat pain. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration in patients with different pain conditions may be very broad. This initiative encourages interdisciplinary collaborations by experts from multiple fieldspharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, and others in relevant fields of inquiry.
|Federal Grant Title:||Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)|
|Federal Agency Name:||National Institutes of Health (HHS-NIH11)|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AT-19-009|
|Type of Funding:||Grant|
|CFDA Descriptions:||Information not provided|
|Current Application Deadline:||March 15th, 2019|
|Original Application Deadline:||March 15th, 2019|
|Posted Date:||January 3rd, 2019|
|Creation Date:||January 3rd, 2019|
|Archive Date:||April 20th, 2019|
|Total Program Funding:|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
|Last Updated:||January 3rd, 2019|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Pri...
- • Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Al...
- • Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R...
- • Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanica...
- • Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clin...
- • Probiotics for Pediatric Illnesses
- • Cam Practitioner Research Education Project Grant Partnership
- • Complementary and Alternative Medicine Career Transition Award (K22)
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...